The appropriate timing of brain radiotherapy for asymptomatic brain metastasis in patients with epidermal growth factor receptor mutant non-small cell lung cancer

Song-ran LIU,Bo QIU,Li-kun CHEN,Fang WANG,Ying LIANG,Pei-qiang CAI,Li ZHANG,Zhao-lin CHEN,Meng-zhong LIU,Hui LIU

DOI: https://doi.org/10.13820/j.cnki.gdyx.20150428.004

2015-01-01

Abstract:Objective To assess the efficacy and appropriate timing of brain radiotherapy administration for asymptomatic brain metastasis (BM) in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer ( NSCLC) .Methods Fifty patients diagnosed as EGFR mutant NSCLC with untreated asymptomatic BM were selected to analyze the treatment outcomes and failure patterns.Results With a median follow-up of 26 months, the 2-year overall survival ( OS) rate was 44.0% and the estimated OS time was 21 months.On univariate analysis, ECOG performance status, other distant metastases and first line systemic treatment were independently associated with OS.The successional multivariate analysis identified only other sites of distant metastases as the prognostic factor.The 2-year brain metastases progression free survival ( BM PFS) rate was 29.3%and the estimated time was 19 months.Wheth-er or not receiving the first-line brain radiotherapy( RT) didn′t show significant association with BM PFS.Conclusions First-line brain RT doesn′t improve OS of this cohort of patients, nor improve BM PFS.The status of systemic disease is the strongest prognostic factor.In treatment-naive NSCLC patients with an EGFR mutation and asymptomatic BM, partic-ularly in those with active systemic disease, first-line tyrosine kinase inhibitor and delayed brain RT may be proper.